INCREASED SERUM OESTRONE AND OESTRADIOL FOLLOWING SPIRONOLACTONE ADMINISTRATION IN HYPERTENSIVE MEN
- 1 December 1978
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 9 (6) , 523-533
- https://doi.org/10.1111/j.1365-2265.1978.tb01510.x
Abstract
SUMMARY: The present study was undertaken to evaluate long‐term effects of spironolactone on basal serum oestrone, oestradiol, testosterone, LH and prolactin concentrations in hypertensive male patients. Serum prolactin response to TRH was also evaluated. Patients were divided into two groups: a conventional‐dosage group, consisting of six males with essential hypertension who took 75 to 150 mg of spironolactone daily for 12 weeks, and a high‐dosage group, consisting of two males with idiopathic hyperaldosteronism who took 300 mg of spironolactone daily for more than 40 weeks.In the conventional‐dosage group, serum oestrone concentrations significantly increased (P > 0.01) at 12 weeks, serum oestradiol concentrations gradually increased throughout the study period, however, the increments were not statistically significant (P > 0.2). Basal serum testosterone, LH and prolactin concentrations were not significantly changed throughout the study period. Enhancement of serum prolactin response to TRH was not found in any of the patients in the conventional‐dosage group.In the high‐dosage group, serum oestrone maintained high levels from the beginning of this study, and serum oestradiol concentrations increased with the development of gynaecomastia. Serum testosterone, LH and prolactin concentrations did not show any definite change throughout the study period.Thus, long‐term spironolactone treatment increased the serum levels of oestrone and oestradiol in hypertensive men followed by the development of gynaecomastia. The elevations in circulating oestrogens could well explain the oestrogenic side‐effects of spironolactone treatment.Keywords
This publication has 32 references indexed in Scilit:
- Gynecomastia and Semen Abnormalities Induced by Spironolactone in Normal MenJournal of Clinical Endocrinology & Metabolism, 1977
- Increased Plasma 11-Deoxycorticosterone During Spironolactone MedicationJournal of Clinical Endocrinology & Metabolism, 1977
- Impaired LH Release Following Exogenous Estrogen Administration in Patients with Amenorrhea-Galactorrhea SyndromeJournal of Clinical Endocrinology & Metabolism, 1976
- Antiandrogenic Effect of Spirolactones: Mechanism of ActionEndocrinology, 1975
- Mode of spironolactone anti-androgenic action: Inhibition of androstanolone binding to rat prostate androgen receptorMolecular and Cellular Endocrinology, 1974
- Letter: Drug-induced gynaecomastia.BMJ, 1974
- Growth Hormone, Thyrotropin and Prolactin Responses to Thyrotropin-Releasing Hormone Following Diethylstilbestrol Pretreatment*Journal of Clinical Endocrinology & Metabolism, 1973
- Simultaneous Radioimmunoassay of Plasma Testosterone and DihydrotestosteroneAnalytical Letters, 1972
- Solid-Phase Radioimmunoassay of Estradiol-17βJournal of Clinical Endocrinology & Metabolism, 1969
- Spironolactone Therapy and GynecomastiaJAMA, 1965